Comparative study on the release of osteogenic and inflammatory factors in advanced platelet-rich fibrin between diabetic and healthy populations

doi:10.12337/zgkqzzxzz.2025.08.007

Abstract

Abstract: Objective To compare the release kinetics of key osteogenic growth factors and inflammatory cytokines in advanced platelet-rich fibrin (A-PRF) between patients with diabetes mellitus (DM) and healthy populations. Methods Participants meeting the inclusion and exclusion criteria were assigned to either the DM group (n=8) or the healthy control group (n=8). Venous blood was centrifuged to prepare A-PRF membranes, and eluates were collected at 15 min, 60 min, 8 h, 1 d, 3 d, 10 d, 14 d, and 21 d post-incubation. The concentrations of platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), epidermal growth factor (EGF), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) were quantified using enzyme-linked immunosorbent assay (ELISA) and analyzed comparatively. Results (1) Cumulative PDGF-BB release from A-PRF in the DM group was consistently lower than that in healthy controls, with statistically significant differences observed from 15 min onward (P<0.01). (2) VEGF release from A-PRF was significantly reduced in the DM group from day 1 to day 21 compared to controls (P<0.01). (3) No statistically significant difference in cumulative EGF release was observed between the two groups (P>0.05). (4) Cumulative TGF-β release from A-PRF was significantly lower in the DM group from day 1 onward (P<0.05). (5) TNF-α release from A-PRF was significantly higher in the DM group than in healthy controls from 8 h onward (P<0.05). (6) No statistically significant difference in cumulative IL-6 release was observed between the two groups (P>0.05). Conclusion Compared to healthy individuals, DM patients exhibited significantly lower cumulative release of osteogenic growth factors (PDGF-BB, VEGF, TGF-β) from A-PRF and elevated levels of the inflammatory cytokine TNF-α. No significant differences were observed in EGF and IL-6 release.

Key words: Advanced platelet-rich fibrin(A-PRF), Diabetes mellitus, Growth factors, Inflammatory factors, Bone healing

Nong Yingjiao, Li Yongwei, Lu Chan, Deng Hanlin, Tang Jiaqin, Li Shujie, Liang Lihua. Comparative study on the release of osteogenic and inflammatory factors in advanced platelet-rich fibrin between diabetic and healthy populations[J]. Chinese Journal of Oral Implantology, 2025, 30(4): 370-376.

References

[1] Meldgaard T, Olesen SS, Farmer AD, et al.Diabetic enteropathy: from molecule to mechanism-based treatment[J]. J Diabetes Res, 2018, 2018:3827301. DOI: 10.1155/2018/3827301.
[2] Abd El-Hameed AM, Eskandrani AA, Salah Abdel-Reheim E, et al. The amelioration effect of antidiabetic agents on cytokine expression in patients with type 2 diabetes mellitus[J]. Saudi Pharm J, 2024, 32(5):102029. DOI: 10.1016/j.jsps.2024.102029.
[3] Bahney CS, Zondervan RL, Allison P, et al.Cellular biology of fracture healing[J]. J Orthop Res, 2019,37(1):35-50. DOI: 10.1002/jor.24170.
[4] 黄李蓉, 冯泽儒, 吴红崑, 等. 富血小板纤维蛋白促进骨再生效果的研究[J]. 中国口腔种植学杂志, 2025, 30(2): 118-126.DOI: 10.12337/zgkqzzxzz.2025.04. 005.
Huang LR, Feng ZR, Wu HK, et al.Effect of platelet-rich fibrin on bone regeneration[J].Chin J Oral Implantol, 2025, 30(2): 118-126. DOI: 10.12337/zgkqzzxzz.2025.04.005.
[5] Bahney CS, Zondervan RL, Allison P, et al.Cellular biology of fracture healing[J]. J Orthop Res, 2019,37(1):35-50. DOI: 10.1002/jor.24227.
[6] Fujioka-Kobayashi M, Miron RJ, Hernandez M, et al.Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response[J]. J Periodontol, 2017, 88(1):112-121. DOI: 10.1902/jop.2016.160443.
[7] El Bagdadi K, Kubesch A, Yu X, et al.Reduction of relative centrifugal forces increases growth factor release within solid platelet-rich-fibrin (PRF)-based matrices: a proof of concept of LSCC (low speed centrifugation concept)[J]. Eur J Trauma Emerg Surg, 2019, 45(3):467-479. DOI: 10.1007/s00068-017-0785-7.
[8] Yang S, Li Y, Liu C, et al.Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction[J]. Front Endocrinol (Lausanne), 2022, 13:949535. DOI: 10.3389/fendo.2022.949535.
[9] Wang F, Ye Y, Zhang Z, et al.PDGFR in PDGF-BB/PDGFR signaling pathway does orchestrates osteogenesis in a temporal manner[J]. Research (Wash DC), 2023, 6:0086. DOI: 10.34133/research.0086.
[10] Liu M, Liu Y, Luo F.The role and mechanism of platelet-rich fibrin in alveolar bone regeneration[J]. Biomed Pharmacother, 2023, 168:115795. DOI: 10.1016/j.biopha.2023.115795.
[11] Zhu G, Zhang T, Chen M, et al.Bone physiological microenvironment and healing mechanism: basis for future bone-tissue engineering scaffolds[J]. Bioact Mater, 2021, 6(11):4110-4140. DOI: 10.1016/j.bioactmat.2021.03.043.
[12] Tito C, Masciarelli S, Colotti G, et al.EGF receptor in organ development, tissue homeostasis and regeneration[J]. J Biomed Sci, 2025, 32(1):24. DOI: 10.1186/s12929-025-01119-9.
[13] Wang T, He C.TNF-α and IL-6: the link between immune and bone system[J]. Curr Drug Targets, 2020, 21(3):213-227. DOI: 10.2174/1389450120666190821161259.
[14] Sghaireen MG, Alduraywish AA, Srivastava KC, et al.Comparative evaluation of dental implant failure among healthy and well-controlled diabetic patients-a 3-year retrospective study[J]. Int J Environ Res Public Health, 2020, 17(14):5253. DOI: 10.3390/ijerph17145253.
[15] Maruyama M, Rhee C, Utsunomiya T, et al.Modulation of the inflammatory response and bone healing[J]. Front Endocrinol (Lausanne), 2020, 11:386. DOI: 10.3389/fendo.2020.00386.
[16] Zhang M, Yu W, Niibe K, et al.The effects of platelet-derived growth factor-BB on bone marrow stromal cell-mediated vascularized bone regeneration[J]. Stem Cells Int, 2018, 2018:3272098. DOI: 10.1155/2018/3272098.
[17] Zheng SY, Wan XX, Kambey PA, et al.Therapeutic role of growth factors in treating diabetic wound[J]. World J Diabetes, 2023, 14(4):364-395. DOI: 10.4239/wjd.v14.i4.364.
[18] Tyndall WA, Beam HA, Zarro C, et al.Decreased platelet derived growth factor expression during fracture healing in diabetic animals[J]. Clin Orthop Relat Res, 2003, (408):319-330. DOI: 10.1097/00003086-200303000-00043.
[19] Hicklin DJ, Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J]. J Clin Oncol, 2005,23(5):1011-27. DOI: 10.1200/JCO.2005.06.081.
[20] Hoff P, Maschmeyer P, Gaber T, et al.Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model[J]. Cell Mol Immunol, 2013, 10(2):151-158. DOI: 10.1038/cmi.2012.56.
[21] Liu J, Pan S, Wang X, et al.Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives[J]. Eur J Med Res, 2023, 28(1):553. DOI: 10.1186/s40001-023-01431-w.
[22] Felmeden DC, Spencer CG, Belgore FM, et al.Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management[J]. Am J Hypertens, 2003, 16(1):11-20. DOI: 10.1016/s0895-7061(02)03149-7.
[23] Saukkonen T, Mutt SJ, Jokelainen J, et al.Adipokines and inflammatory markers in elderly subjects with high risk of type 2 diabetes and cardiovascular disease[J]. Sci Rep, 2018, 8(1):12816. DOI: 10.1038/s41598-018-31144-8.
[24] Dandona P, Aljada A, Mohanty P, et al.Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9[J]. Diabetes Care, 2003, 26(12):3310-3314. DOI: 10.2337/diacare.26.12.3310.
[25] Klimontov VV, Mavlianova KR, Orlov NB, et al.Serum cytokines and growth factors in subjects with type 1 diabetes: associations with time in ranges and glucose variability[J]. Biomedicines, 2023, 11(10):2843. DOI: 10.3390/biomedicines11102843.
[26] Tsalamandris S, Antonopoulos AS, Oikonomou E, et al.The role of inflammation in diabetes: current concepts and future perspectives[J]. Eur Cardiol, 2019, 14(1):50-59. DOI: 10.15420/ecr.2018.33.1.
[27] Alavi A, Sibbald RG, Mayer D, et al. Diabetic foot ulcers: part I. pathophysiology and prevention[J]. J Am Acad Dermatol, 2014,70(1):1.e1-e18; quiz 19-20. DOI: 10.1016/j.jaad.2013.06.055.
[28] Okizaki S, Ito Y, Hosono K, et al.Suppressed recruitment of alternatively activated macrophages reduces TGF-β1 and impairs wound healing in streptozotocin-induced diabetic mice[J]. Biomed Pharmacother, 2015,70:317-25. DOI: 10.1016/j.biopha.2014.10.020.
[29] Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al.Macrophage plasticity, polarization, and function in health and disease[J]. J Cell Physiol, 2018,233(9):6425-6440. DOI: 10.1002/jcp.26429.
[30] Liu Y, Zhang Y, Zheng Z, et al.Incorporation of NGR1 promotes bone regeneration of injectable HA/nHAp hydrogels by anti-inflammation regulation via a MAPK/ERK signaling pathway[J]. Front Bioeng Biotechnol, 2022, 10:992961. DOI: 10.3389/fbioe.2022.992961.
[31] Liu C, Jiang D.High glucose-induced LIF suppresses osteoblast differentiation via regulating STAT3/SOCS3 signaling[J]. Cytokine, 2017, 91:132-139. DOI: 10.1016/j.cyto.2016.12.016.
[32] Wu M, Wu S, Chen W, et al.The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease[J]. Cell Res, 2024, 34(2):101-123. DOI: 10.1038/s41422-023-00918-9.
[33] Roohi A, Tabrizi M, Abbasi F, et al.Serum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and age-matched healthy controls[J]. Biomed Res Int, 2014, 2014:718946. DOI: 10.1155/2014/718946.
[34] Li Z, Zhang B, Shang J, et al.Diabetic and nondiabetic BMSC-derived exosomes affect bone regeneration via regulating miR-17-5p/SMAD7 axis[J]. Int Immunopharmacol, 2023, 125(Pt B):111190. DOI: 10.1016/j.intimp.2023.111190.
[35] Willeumier JJ, van der Hoeven NM, Bollen L, et al. Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer[J]. Bone Joint J, 2017, 99-B(4):516-521. DOI: 10.1302/0301-620X.99B4.BJJ-2016-0872.R1.
[36] Lundquist R, Holmstrøm K, Clausen C, et al.Characteristics of an autologous leukocyte and platelet-rich fibrin patch intended for the treatment of recalcitrant wounds[J]. Wound Repair Regen, 2013, 21(1):66-76. DOI: 10.1111/j.1524-475X.2012.00870.x.
[37] Hu F, Wang X, Liang G, et al.Effects of epidermal growth factor and basic fibroblast growth factor on the proliferation and osteogenic and neural differentiation of adipose-derived stem cells[J]. Cell Reprogram, 2013, 15(3):224-232. DOI: 10.1089/cell.2012.0077.
[38] Wang Guoxia,Yang Yu,Zhang Shuai,et al.Beta-carotene regulates the biological activity of EGF in IEC6 cells by alleviating the inflammatory process[J]. Cell Cycle, 2022,21(16):1726-1739. DOI: 10.1080/15384101.2022.2067676.
[39] Jung SM, Kim KW, Yang CW, et al.Cytokine-mediated bone destruction in rheumatoid arthritis[J]. J Immunol Res, 2014, 2014:263625. DOI: 10.1155/2014/263625.
[40] Ping SH, Tian FM, Liu H, et al.Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis[J]. Bosn J Basic Med Sci, 2021,21(3):284-293. DOI: 10.17305/bjbms.2020.5142.